Dr. Ying Zhang is currently working as a postdoc research fellow in Program of Cellular and Molecular Medicine at Boston Children’s Hospital/Harvard Medical School. She has completed her B.S. in Biological Sciences in 2009 from Nankai University, Tianjin, China. She performed her PhD studies in the cell and molecular biology program at Perelman School of Medicine, University of Pennsylvania and was graduated in August 2016. She is trained as an immunologist and is passionate to pursue a broad spectrum of research questions from basic to translational immunology, with specific research interests in immunometabolism, cancer immunology and immunotherapy. Her study on metabolic reprograming of tumor-infiltrating T cells has been published in Cancer Cell in 2017, and her work have also been published in Cancer Research, Frontiers in Immunology, Journal of Immunology, Oncotarget et al. She isalso an inventor of two patents; one of them has been commercialized for veterinary melanoma vaccine development. In addition, Dr. Zhang is an active reviewer for a number of journals and publishing groups, such as the BMJ, Peer J, Dove medical press journals, and Scientific Research Publishing et al.
Her current work focuses on developing novel immune-modulating aptamer-siRNA drugs to improve the immunotherapeutic efficacy for patients with triple-negative and HER2+ breast cancers; as well as dissecting the role of pyroptosis in cancer development and its application for cancer immunotherapy.